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Abstract
Background: Recently, intra-articular botulinum toxin A (IA BoNT A) has been shown to reduce joint pain in
osteoarthritic dogs. Similar results have been reported in human patients with arthritis. However, the mechanism of
the antinociceptive action of IA BoNT A is currently not known. The aim of this study was to explore this
mechanism of action by investigating the effect of IA BoNT A on synovial fluid (SF) and serum substance P (SP),
prostaglandin E2 (PGE2), and tumor necrosis factor alpha (TNF-α) in osteoarthritic dogs. Additionally, the aim was to
compare SF SP and PGE2 between osteoarthritic and non-osteoarthritic joints, and investigate associations between
SP, PGE2, osteoarthritic pain, and the signalment of dogs. Thirty-five dogs with chronic naturally occurring
osteoarthritis and 13 non-osteoarthritic control dogs were included in the study. Osteoarthritic dogs received either
IA BoNT A (n = 19) or IA placebo (n = 16). Serum and SF samples were collected and osteoarthritic pain was
evaluated before (baseline) and 2 and 8 weeks after treatment. Osteoarthritic pain was assessed with force platform,
Helsinki Chronic Pain Index, and joint palpation. Synovial fluid samples were obtained from control dogs after
euthanasia. The change from baseline in SP and PGE2 concentration was compared between the IA BoNT A and
placebo groups. The synovial fluid SP and PGE2 concentration was compared between osteoarthritic and control
joints. Associations between SP, PGE2, osteoarthritic pain, and the signalment of dogs were evaluated.
Results: There was no significant change from baseline in SP or PGE2 after IA BoNT A. Synovial fluid PGE2 was
significantly higher in osteoarthritic compared to control joints. Synovial fluid PGE2 correlated with osteoarthritic
pain. No associations were found between SP or PGE2 and the signalment of dogs. The concentration of TNF-α
remained under the detection limit of the assay in all samples.
Conclusions: The results suggest that the antinociceptive effect of IA BoNT A in the joint might not be related to
the inhibition of SP nor PGE2. Synovial fluid PGE2, but not SP, could be a marker for chronic osteoarthritis and pain
in dogs.
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Background
Osteoarthritis (OA) is the most common joint disease in
dogs often cited to affect one fifth of the dog population
over 1 year of age [1]. The most important clinical mani-
festation of OA is joint pain, which is characterized by
hyperalgesia and pain at rest [2]. In a hyperalgesic joint
the pain sensitivity is intensified because of sensitization
in the nociceptive system. The sensitization is the result
of a complex action of various inflammatory mediators,
including pro-inflammatory cytokines, prostaglandins,
and neuropeptides [2, 3].
Substance P (SP) is one of the principal neurotrans-
mitters of pain in arthritis [2, 4, 5]. Substance P is
produced in the cell bodies of the nociceptive afferent
nerve fibers, and it is involved in the transmission of
noxious stimuli from the joint into the spinal cord [4].
Following the activation of the afferent nerve fibers, SP
is antidromically released from the nerves into the joint
causing neurogenic inflammation and promoting periph-
eral sensitization [2, 4]. Increased level of SP in synovial
fluid (SF) has been related both to OA and to joint pain
in horses [6, 7], and the upregulation of SP-positive nerve
fibers in the joint is associated with painful OA in human
patients [8]. Nerve fibers containing SP have been found
in various joint structures of dogs [9–11]; and recently,
the concentration of SP in the spinal cord has been associ-
ated with central sensitization and pain in dogs with
experimental OA [12]. However, to our knowledge the SF
SP concentration and its association with osteoarthritic
pain have not been studied in this species.
Prostaglandin E2 (PGE2) is a potent inflammatory me-
diator involved in both peripheral and central nocicep-
tive pathways in OA [3, 13]. It is produced by the action
of the cyclooxygenase (COX) enzymes in various cells
[3]. The SF concentration of PGE2 correlates positively
with osteoarthritic pain in dogs [14], horses [15], and
humans [16, 17]. Substance P enhances the release of
PGE2 from chondrocytes [18], and the concentrations of
SP and PGE2 correlate with each other in the SF of
osteoarthritic horses [6].
Tumor necrosis factor alpha (TNF-α) is one of the
principal proinflammatory cytokines involved in the
pathophysiology and pain of OA [3, 19, 20]. It is pro-
duced in various cells in the joint and it drives forward
the inflammatory cascade by inducing the expression of
other inflammatory and catabolic factors including PGE2
[20]. The SF TNF-α concentration is elevated in osteo-
arthritic dogs [21], horses [22], and humans [20]. The SF
level of TNF-α correlates positively with pain in osteo-
arthritic human patients [23]. The correlation between
the SF level of TNF-α and osteoarthritic joint pain has
not been previously investigated in dogs.
Botulinum neurotoxin A (BoNT A) is a strong neuro-
toxin with antinociceptive effects. In the neuromuscular
junction, BoNT A blocks the release of acetylcholine,
which leads to muscle relaxation and pain relief [24].
However, the pain relief is not only related to the reduction
in the muscle tone, but also to a direct antinociceptive
effect of the toxin [24, 25]. In addition to acetylcholine,
BoNTA inhibits the exocytosis of various other substances
associated with inflammation and pain. Among others,
BoNT A has been shown to inhibit the release of SP in rat
dorsal root ganglia neurons [26] and in isolated rabbit iris
muscles [27]; and BoNTA injections have suppressed pain,
inflammation, and COX-2 expression in the prostate and
bladder of rats [28, 29]. Finding the antinociceptive and
anti-inflammatory effects of BoNT A has led to studies
investigating its efficacy as an intra-articular (IA) injection
in the treatment of arthritic pain in various species.
Intra-articular injection of BoNT A reduced joint
pain in osteoarthritic dogs in our recent placebo-
controlled, double-blinded clinical trial [30]. Similar
results have been reported in human patients with arth-
ritis [31–34], and in induced inflammatory arthritis in
experimental horses and mice [31, 35]. Despite these
promising results, the mechanism of the antinociceptive
action of the toxin inside the joint has not been previously
investigated.
The purpose of our study was to explore the mechan-
ism of this antinociceptive action by investigating the
effect of IA BoNT A on the concentrations of SP, PGE2,
and TNF-α in the SF and serum of osteoarthritic dogs.
The hypothesis was that their concentration decreases
significantly after an IA BoNT A injection, which could
explain the antinociceptive effect of the toxin in the
joint. Additionally, our purpose was to compare the SF
concentrations of SP and PGE2 between osteoarthritic
and non-osteoarthritic control joints, and to investigate
whether their concentration correlates with osteoarthritic
pain in dogs. We also evaluated associations between
these pain mediators and the signalment of the dogs.
Methods
Animals
Synovial fluid and serum samples were collected from
privately owned osteoarthritic dogs. The dogs were in-
cluded in our previous study on IA BoNT A in the treat-
ment of osteoarthritic joint pain in dogs [30]. The study
was approved by the Animal Experiment Board (ESAVI-
2010-04178/Ym-23) and the Finnish Medicines Agency.
The owners of the dogs signed an informed consent form
having received information on the study. The inclusion
criteria were chronic lameness present for at least
3 months, the diagnosis of OA in the stifle, elbow, or hip
joint verified by radiographs, and pain on palpation of the
joint. The exclusion criteria were lameness not related to
OA, a neurological, systemic or infectious disease, age less
than one year, and weight less than 15 kg. Also, the dogs
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were excluded if they had received any IA treatment,
corticosteroids, or pentosan polysulphate injection in less
than one month before the study, or treatment with non-
steroidal anti-inflammatory drugs or tetracyclines in less
than 1 week before the study. The dogs were screened for
participation in the study as described previously [30].
Synovial fluid samples were also collected from dogs
without OA. These dogs served as non-osteoarthritic
controls. The dogs were privately owned and donated
for research at the University of Helsinki after euthan-
asia. The exclusion criteria were history of joint disease,
age less than 1 year, weight less than 15 kg, and the
above-mentioned medications. The sampled joints were
confirmed healthy by SF analysis, macroscopical evalu-
ation, and histopathological examination of biopsies
taken from the weightbearing areas of the articular
cartilage, the subchondral bone, and the synovium. The
criteria for the histopathological assessment were modi-
fied from the OARSI Initiative [36]. The samples were
excluded from the study, if there were any macroscopical
alterations in the articular cartilage or synovium, if the
total SF cell count was more than 2.0 × 109/L [37], if
there were more than 6% of neutrophils in the SF differ-
ential cell count [37], or if there were considerable
abnormal findings in the histopathological examination.
Study design
The study was carried out as a placebo-controlled, ran-
domized, double-blinded clinical trial with stratified
parallel group design. The dogs were stratified into six
groups based on the administration of treatment into
the stifle, elbow, or hip joint and on moderate or severe
joint pain evaluated by Helsinki Chronic Pain Index
(HCPI). The grouping for joint pain severity was based
on the median of the HCPI results acquired from a
screening visit. A moderate pain score was ≤16, and a
severe pain score was ≥17. Randomization was per-
formed using randomly permuted blocks. Dogs were
randomized within each stratum in blocks of two in a
1:1 ratio to receive an IA injection of either 30 IU of
BoNT A1 or an equivalent volume of placebo (0.3 mL
sterile 0.9% saline) into the osteoarthritic joint. The
randomization list was generated using SAS/Proc Plan2
and provided by a statistician to the research technician,
who prepared the treatment for each dog following the
list and covered the syringes with non-transparent tape.
The dog owners, the veterinarians performing the trial,
and the laboratory personnel participating in the
analyses were masked to treatment allocation.
Study procedure
Intra-articular injection and arthrocenteses
The osteoarthritic dogs were sedated for the IA injection.
Sedation was accomplished by intramuscular injection of
medetomidine (0.01 mg/kg) and butorphanol (0.1 mg/kg),
or only butorphanol depending on the age of the animal.
The sedation was followed by intravenous propofol
anesthesia, if necessary. Synovial fluid and serum samples
were obtained from the osteoarthritic dogs (IA BoNT A
and placebo groups) before (baseline) and at 2 and 8 weeks
after the IA medication.
The non-osteoarthritic control dogs were sedated by
intramuscular injection of dexmedetomidine (10 μg/kg)
and butorphanol (0.2 mg/kg) after which euthanasia was
performed by intravenous propofol (10 mg/kg) and thio-
pental sodium (50 mg/kg). The SF sample was collected
by arthrocentesis either from the stifle, elbow, or hip
joint immediately after euthanasia. The joint was macro-
scopically evaluated after the arthrocentesis after which
biopsies were taken and fixed in 10% neutral buffered
formalin, embedded in paraffin wax, sectioned routinely,
and stained with hematoxylin and eosin as well as tolui-
dine blue for histopathological evaluation. The samples
from bone were decalcified in EDTA-solution before
embedding. No serum samples were collected from the
control dogs.
Processing of samples
The SF samples were processed within 30 minutes after
the arthrocentesis. A part of the SF sample was sepa-
rated into an EDTA tube for analyzing the total and
differential cell counts. The rest of the sample was put
into sterile Eppendorf-tubes, which were centrifuged at
10 000 rpm for 15 min. The supernatant was separated
and stored in −80 °C.
The serum samples were taken into serum separating
tubes and left to stand for 30 min, after which they were
centrifuged at 3 500 rpm for 10 min. The serum was
separated and stored in −80 °C.
Sample analysis
The pain mediators were analyzed with commercially
available ELISAs. The ELISAs for SP3 and PGE2
4 are not
validated for dogs, but because of the homologous
nature of both molecules between species, the manufac-
turers report that these assays are suitable for evaluating
canine samples. The ELISA for TNF-α5 is validated for
canine serum and plasma, according to the manufac-
turer of the test.
All analyses were performed on both SF and serum.
Samples were analyzed in duplicate according to the
manufacturers’ instructions.
For SP and PGE2, the assay accuracy was determined
by evaluation of dilution parallelism. For TNF-α, the
assay accuracy was determined by evaluation of a canine
TNF-α control provided by the manufacturer and per-
forming a spiking recovery test in SF and serum. Assay
performance of each kit was monitored by the evaluation
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of a control SF sample included in each kit. All SF and
serum samples of each dog were analyzed in the same
plate of each assay.
Substance P
The concentration of SP was measured with an assay3
based on a competitive binding technique, in which the
intensity of the colorimetric signal is inversely propor-
tional to the concentration of SP in the sample. The
concentration of SP was reported as pg/mL. The detec-
tion limit of the assay was 3.9 pg/mL, as reported by the
manufacturer.
For SP, the dilution parallelism was evaluated by assay-
ing the sample undiluted and at dilutions 1:2, 1:5, and
1:10. The concentration of SP was higher in the diluted
samples, which can be explained by an increase in the
ratio of the high affinity antiserum to the SP binding
proteins [38, 39]. Because our samples were on the low
concentration range for this assay, the samples were
assayed undiluted. No extraction was performed for the
samples before the assay, because extraction results in
loss of inconsistent amounts of SP [38, 39].
The intra assay coefficient of variation (CV) was 11.4%
for SF and 11.8% for serum. The inter assay CV was 19.3%.
Prostaglandin E2
The concentration of PGE2 was measured with an assay
4
employing forward sequential competitive binding tech-
nique. In this technique, the intensity of the colorimetric
signal is inversely proportional to the concentration of
PGE2 in the sample. The concentration of PGE2 was
reported as pg/mL. The detection limit of the assay was
13.4 pg/mL, as reported by the manufacturer.
For PGE2, the sample was assayed undiluted and at
dilutions 1:2, 1:5, 1:10, and 1:20. Good assay linearity
was achieved by dilutions. One in 20 was considered the
optimal dilution for the SF samples and either 1:20 or
1:50 was considered the optimal dilution for the serum
samples, depending on the concentration of PGE2. To
test for a possible matrix interference in the PGE2
analysis, the linearity of the results from both diluted
and non-diluted samples with and without extraction
was evaluated. No extraction was considered neces-
sary because of the consistent results of the extracted
and unextracted samples. The samples were diluted in
assay buffer.
The intra assay CV was 10.5% for SF and 9.1% for
serum. The inter assay CV was 18.0%.
Tumor necrosis factor alpha
The concentration of TNF-α was measured with an
assay5 applying quantitative sandwich enzyme immuno-
assay technique, in which the intensity of the colorimet-
ric signal is in proportion to the concentration of TNF-α
in the sample. The concentration of TNF-α was reported
as pg/mL. The detection limit of the assay was 2.4 pg/mL,
as reported by the manufacturer.
A canine TNF-α control provided by the manufacturer
was added in each plate to determine the assay accuracy.
A spiking recovery test was performed by determining
the recovery rate of this canine TNF-α control in SF and
serum. Because the concentration of TNF-α remained
below the detection limit of the assay in all the samples
analyzed, no intra or inter assay CVs could be calculated.
Clinical variables of osteoarthritic pain
The osteoarthritic pain was evaluated at baseline and at
2 and 8 weeks after the IA medication in the osteoarth-
ritic dogs (IA BoNT A and placebo groups). The clinical
variables of osteoarthritic pain were the ground reaction
forces peak vertical force (PVF) and vertical impulse
(VI), HCPI, and pain on palpation of the joint.
The ground reaction forces were measured with a
force platform6and a computer software program7 at trot
at a comfortable speed. Hind limb data were obtained
from dogs with stifle and hip osteoarthritis, and fore
limb data were obtained from dogs with elbow osteo-
arthritis. The acceptable range for the velocity of a trial
was ± 0.5 m/s around the mean velocity of each dog and
the acceptable range for acceleration was ≤ ±0.5 m/s2.
The mean velocity of each dog was calculated when the
study had ended and all trials had been obtained. Three
to five valid trials were chosen for each dog at each visit,
and their mean was used for analysis. All forces were
normalized to bodyweight in kilograms. The HCPI ques-
tionnaire included questions regarding dog’s behaviour
and demeanor during a 1 week period, as described by
Hielm-Björkman [40], and it was always answered by the
same dog owner. The veterinarian evaluated the pain on
palpation of the joint using a five-point scale from 0 to 4
(0, no sign of pain; 1, mild pain (dog turns head in
recognition); 2, moderate pain (dog pulls limb away); 3,
severe pain (dog vocalizes or becomes aggressive); and 4,
extreme pain (dog does not allow palpation).
The control dogs were not evaluated for osteoarthritic
pain.
Statistical analysis
All the continuously distributed variables were tested
for normality using the Shapiro-Wilk test. Data were
expressed as mean and standard deviation (SD) (nor-
mally distributed data) or as median and interquartile
range (IQR) (non-normally distributed data). All of
the statistical modelling was conducted using logarith-
mic transformed data for all of the pain mediators to
normalize the distributions. The differences in the sig-
nalment of the groups of dogs (IA BoNT A, placebo,
and controls) were analyzed using one-way analysis-
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of-variance (ANOVA) (continuous variables) or Fisher’s
exact test (categorical variables). The differences between
the treatment groups (IA BoNT A vs placebo) in change
from baseline (at 2 and 8 weeks) in the mean SF and
serum pain mediator concentrations were analyzed with
linear mixed models for repeated measures (RM-
ANCOVA). The models included the treatment group,
time point, and the interaction of treatment group and
time point as fixed terms, the baseline value of the pain
mediator as a covariate, and dog as a random term. An
unstructured covariance structure was applied in the
model. Tukey-Kramer multiplicity adjustment method
was used to correct the p-values of the multiple treatment
comparisons. The differences in the SF pain mediator
concentrations at baseline between osteoarthritic (pooled
treatment groups) and control dogs were analyzed using
Mann-Whitney U-tests. For the osteoarthritic dogs
(pooled treatment groups) the differences in pain medi-
ator concentrations between SF and serum at baseline
were analyzed using Wilcoxon matched-pair signed rank
tests. The correlations among the clinical variables of
osteoarthritic pain and SF and serum pain mediator
concentrations in osteoarthritic dogs (pooled treatment
groups) were assessed by analyzing either the Pearson’s
correlation coefficient (normally distributed data) or the
Spearman’s rank correlation coefficient (non-normally
distributed data) at baseline. The associations between SF
and serum pain mediator concentrations and signalment
of the dogs (IA BoNT A, placebo, and controls) were ana-
lyzed by using Fisher’s exact test. All tests were performed
two-tailed and significance was set at P < 0.05. Statistical
analysis was performed with statistical software2.
Results
Animals
Forty-eight dogs were included in the study. Thirty-five
were osteoarthritic dogs, from which 19 were allocated
to the IA BoNT A group and 16 to the placebo group.
Thirteen were non-osteoarthritic control dogs. There
were no significant differences between the groups of
dogs in age, weight, gender, duration of lameness, or
sampled joint (Table 1).
Substance P analysis
In osteoarthritic dogs, SF and serum SP concentrations
were not statistically different in the IA BoNT A group
compared to the placebo group at baseline (P = 0.180
and P = 0.683, respectively). No significant change from
baseline in SF or serum SP concentrations was found in
either group during the study (P = 0.119 and P = 0.148
for overall change in SF and serum in the IA BoNT A
group; P = 0.230 and P = 0.613 for overall change in SF
and serum in the placebo group) (Fig. 1). No significant
difference was detected between the IA BoNT A and
placebo groups in the change from baseline during the
study (P = 0.952 for SF and P = 0.176 for serum).
The SF SP concentration was not statistically differ-
ent in osteoarthritic dogs compared to control dogs,
P = 0.204 (Fig. 2).
Prostaglandin E2 analysis
In osteoarthritic dogs, SF and serum PGE2 concentra-
tions were not statistically different in the IA BoNT
A group compared to the placebo group at baseline
(P = 0.353 and P = 0.052, respectively). No significant
change from baseline in SF or serum PGE2 concen-
trations was found in either group during the study
(P = 0.105 and P = 0.907 for overall change in SF and
serum in the IA BoNT A group; P = 0.726 and P = 0.863
for overall change in SF and serum in the placebo group)
(Fig. 3). No significant difference was detected between
the IA BoNT A and placebo groups in the change from
baseline during the study (P = 0.475 for SF and P = 0.963
for serum).
The SF PGE2 concentration was significantly
higher in osteoarthritic dogs compared to control
dogs, P = 0.001 (Fig. 2).
Tumor necrosis factor alpha analysis
In osteoarthritic dogs, both the SF and serum TNF-α
concentrations were below the detection limit of the
assay in all samples. Because of this, TNF-α was not
measured from the control dogs.
Correlations and associations
In osteoarthritic dogs, SF PGE2 concentration correlated
negatively with the ground reaction forces PVF and VI
and positively with pain on palpation of the joint at
baseline (Fig. 4). Serum PGE2 correlated negatively with
serum SP concentration. No other correlations were
detected between serum pain mediators, SF pain media-
tors, and the clinical variables of osteoarthritic pain. The
correlations are given in detail in Table 2. No associations
were detected between the pain mediators and the age,
weight, gender, duration of lameness, or the sampled joint.
Discussion
Intra-articular BoNT A reduces joint pain in osteoarth-
ritic dogs [30] and human patients [31–33]. However,
the antinociceptive mechanism of action of IA BoNT A
in the joint is currently not known. In this study, we
investigated the effect of IA BoNT A on SF and serum
concentrations of SP, PGE2, and TNF-α in osteoarthritic
dogs. We analyzed these pain mediators at baseline and
at 2 and 8 weeks after treatment with IA BoNT A or
placebo (0.9% saline).
The antinociceptive effect of IA BoNT A in the joint
has been suggested to result from inhibition in the
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release of various inflammatory mediators and neuro-
transmitters [31, 32, 41]. However, this hypothesis is
based on studies made in animal models and in vitro as
no studies have been performed in a clinical setting
neither in animals nor in humans. Botulinum toxin A
has inhibited the release of SP, calcitonin gene-related
peptide (CGRP), glutamate, and COX-2 in cell cultures
[26, 42, 43], in tissue [27, 44–46], and in animal models
of pain [28, 47, 48]. Our decision to measure SP was
based on these findings. In addition, we measured PGE2
because of its association with osteoarthritic pain in dogs
[14], and TNF-α due to its established role in the patho-
physiology of osteoarthritic pain [2, 3, 20].
Somewhat surprisingly, we did not detect any signifi-
cant change in the SF SP or PGE2 concentration in the
IA BoNT A treated dogs during a follow-up time of
8 weeks. The explanation might be that contrary to the
previous hypothesis, the antinociceptive effect of the
toxin in the joint is not based on the inhibition of SP,
nor in the inhibition of PGE2. Our hypothesis of the
inhibition of PGE2 does not receive support from these
data, although COX-2 is a key enzyme in PGE2 produc-
tion [49] and BoNT A inhibits COX-2 [28, 29]. The
toxin might have its effect by inhibiting other neuro-
transmitters, such as CGRP and glutamate, both of
which are associated with pain in OA [8, 50].
Table 1 Signalment of dogs
Variable Osteoarthritic dogs Control dogs
IA BoNT A group Placebo group
n = 19 n = 16 n = 13
Gender
Female/neutered female 2/7 7/2 4/0
Male/neutered male 5/5 5/2 6/3
Weight (kg)
Mean (SD) 33.0 (7.9) 33.2 (10.0) 34.9 (10.9)
Age (years)
Mean (SD) 7.3 (3.0) 5.3 (3.1) 6.0 (3.2)
Duration of lameness
3–< 6 months 1 2 Not applicable
6–12 months 2 6
> 12 months 16 8
Sampled joint
Knee 6 5 7
Elbow 8 6 3
Hip 5 5 3
Breed (number of dogs) Labrador retriever (6) Labrador Retriever (4) Mixed Breed (3)
German Shepherd (3) Bernese Mountain German Shepherd
Collie (2) Dog (2) (2)
Basset Hound (1) Nova Scotia Duck Bernese Mountain
Beauceron (1) Tolling Retriever (2) Dog (1)
Belgian Shepherd (1) Rottweiler (2) Boxer (1)
Cockerspaniel (1) Black Russian Bracco Italiano (1)
Flat-Coated Terrier (1) Dalmatian (1)
Retriever (1) Catalan Sheepdog (1) Dobermann (1)
Irish Setter (1) Central Asian Great Dane (1)
Rottweiler (1) Shepherd Dog (1) Rottweiler (1)
Mixed Breed (1) Siberian Husky (1) Siberian Husky (1)
Wales Springer
Spaniel (1)
Mixed Breed (1)
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Another explanation for not detecting a significant
change in the pain mediator concentrations after IA
BoNT A injection might be that the clinical effect of the
toxin on pain was only mild. Although we have previ-
ously reported significant improvement from baseline in
the IA BoNT A group compared to the placebo group
after treatment [30], the pain relief might not have been
strong enough to be detected as a significant change in
the pain mediators’ concentrations.
In addition to the effects of IA BoNT A on SF and
serum pain mediators, we also compared the SF PGE2 and
SP concentrations between healthy joints and joints with
chronic, naturally occurring OA in dogs. We also investi-
gated whether their concentration correlates with clinical
variables of osteoarthritic pain and whether any associa-
tions exist between the pain mediators and the age,
weight, gender, duration of lameness, or the sampled joint.
The PGE2 concentration was significantly higher in
osteoarthritic compared to healthy dogs (P = 0.001). Pre-
viously, elevated PGE2 concentration has been reported
in osteoarthritic joints of horses [6, 51] and an increase
in SF PGE2 has been documented in experimental dogs
after cranial cruciate ligament transection [14]. It has
been speculated, that the level of SF PGE2 would peak in
the early phase of OA [6, 14]. However, our results show,
that the SF PGE2 concentration is also significantly
increased in chronic OA in dogs.
We detected a positive correlation between the SF PGE2
concentration and joint pain in osteoarthritic dogs at base-
line. The SF PGE2 correlated negatively with the ground
reaction forces PVF and VI (r = −0.619, P = 0.001, and
r = −0.613, P = 0.001; respectively), which indicates less
weight bearing on joints with higher concentration of
PGE2. In addition, the SF PGE2 concentration correlated
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Fig. 1 Synovial fluid (a) and serum (b) SP in osteoarthritic dogs treated
with IA BoNT A or placebo. The concentrations are presented as
median and interquartile range. A: n = 12 for the IA BoNT A group,
n = 7 for the placebo group; B: n = 17, n = 16; respectively
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B
Fig. 2 Synovial fluid PGE2 (a) and SP (b) concentrations in
osteoarthritic and control joints. The central horizontal line indicates
the median value and the boxes indicate the IQR. The top and bottom
whiskers represent the highest and lowest case within 1.5 times of IQR,
respectively. Values more than 1.5 times IQR are labelled outliers and
represented as dots. *Values differ significantly (P = 0.001)
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positively with pain on palpation of the osteoarthritic joint
(r = 0.446, P = 0.017). This is in accordance with the study
by Trumble et al. [14], in which the SF PGE2 concentra-
tion correlated with various pain measures in dogs with
experimental OA, and with the study by van Loon et al.
[15], in which it correlated with pain and lameness in
horses with experimentally induced synovitis. Positive
correlation between PGE2 and an index of pain, stiffness,
and physical disability has also been reported in osteoarth-
ritic human patients [16]. To the authors’ knowledge, this
correlation has not been previously studied in dogs with
chronic, naturally occurring OA.
Contrary to the SF PGE2, serum PGE2 did not correl-
ate with the clinical variables of pain in our study. Serum
PGE2 was approximately threefold higher than the SF
PGE2 (P = 0.000) in the osteoarthritic dogs, which sug-
gests that the local production of PGE2 is important for
the perception of joint pain in OA in dogs and that the
serum PGE2 level is affected by other factors. Therefore,
our study suggests that SF but not serum PGE2 might
have a role as a marker of chronic pain in naturally
occurring OA in dogs.
In contrast, SF SP appeared not to be a good indicator
for osteoarthritic joint pain in our study. Contrary to the
studies in horses [6, 7] and humans [8], we did not de-
tect any significant difference in the SF SP between
osteoarthritic and healthy joints. Also, we found no
correlation between the degree of joint pain and the SF
SP in osteoarthritic dogs. Our finding is in accordance
with the study by van Loon et al. [15], in which IA
morphine reduced lameness without affecting the SF SP
concentration in horses. However, contradictory results
have also been reported [7]. A positive correlation be-
tween SP and joint pain has been documented in human
patients [52], but no correlation [53, 54], and a negative
correlation has also been published [55]. In dogs, the
concentration of SP in the cerebrospinal fluid has been
associated with pain in syringomyelia [56], but to the
authors’ knowledge, its concentration in SF and its asso-
ciation with joint pain has not been previously studied
in this species.
We found a negative correlation between the serum
PGE2 and SP concentrations (r = −0.478, P = 0.004). This
was unexpected, and might not be of clinical relevance.
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Fig. 3 Synovial fluid (a) and serum (b) PGE2 in osteoarthritic dogs
treated with IA BoNT A or placebo. The concentrations are presented
as median and interquartile range. A: n = 12 for the IA BoNT A group,
n = 7 for the placebo group; B: n = 17, n = 16; respectively
Fig. 4 Scatter plots of synovial fluid and serum pain mediators vs clinical
variables of pain in osteoarthritic dogs. Synovial fluid PGE2 was found to
correlate with all the three clinical variables of pain, P< 0.05. No other
correlations were detected. The correlations were measured in
osteoarthritic dogs at baseline. SF = synovial fluid; PGE2 = prostaglandin
E2; SP = substance P; PVF = peak vertical force, VI = vertical impulse
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Previously, a positive correlation has been reported
between SP and PGE2 in SF in horses [6].
We did not detect any TNF-α in the SF or serum
samples of the osteoarthritic dogs in our study, and
because of this, we did not measure TNF-α from the
non-osteoarthritic control dogs. However, to rule out a
problem in the assay, we determined the recovery rate of
a known amount of TNF-α in the SF and serum samples
and were able to obtain consistent results. Also, in a
study by Carter et al. [57] TNF-α activity was detected
in only 2 out of 80 osteoarthritic canine SF samples.
Using a variety of assay methods, previous studies have
found higher [21] and lower [58] concentrations of
TNF-α in osteoarthritic compared to normal joints of
dogs; and in the light of these findings, it would have
been interesting to measure TNF-α also from the control
dogs in our study. The discrepancy between the results
of the previous studies has been explained by loss of
TNF-α activity during storage, presence of specific in-
hibitors in the SF, transient peaks in TNF-α activity
during the disease, and different methods of sample
preparation [21, 57, 58]. However, not detecting any
TNF-α in our osteoarthritic dogs might also be ex-
plained by the chronicity of the disease, as the level of
TNF-α has previously been reported to be higher in
acute severe joint disease compared to joint disease in
general [59], but conflicting findings have also been
recently published [22, 60].
The number of samples in our pain mediator analyses
in the IA BoNT A and placebo groups was quite small
(n = 12 and n = 7, respectively), because we were not able
to collect enough SF for the analyses from all dogs at
every visit. We collected raw SF samples and opted not
to use a lavage method [61] to increase sample volume
because we did not want the lavage to interfere with the
biomarker analysis or with the effects of the toxin.
One limitation in our study is that although the
healthy joints in our study went through a very thorough
evaluation to exclude any disease process, we did not
check the contralateral joints in all of these animals.
Four out of the 13 healthy joint samples were pooled
samples from both stifle, elbow, or hip joints. This was
necessary to provide sufficient SF for the analysis, be-
cause the amount of SF was very small in some healthy
joints. In the non-pooled samples, there is a possibility
that a disease process in the contralateral joint would
have affected the concentration of the SF pain media-
tors in the joint used as a healthy control in our
study. This is especially noteworthy for SP, because
the levels of this neurotransmitter have been reported
to interrelate with each other in bilateral joints via a
neurogenic mechanism [62, 63].
A further limitation in our study is that in the process
of preparing this manuscript, the manufacturer of the SP
ELISA reported finding a 100% cross-reactivity between
SP and a recently found neuropeptide hemokinin-1
(HK-1) in human samples in their assay. Hemokinin-1
binds to the same receptors as SP with similar affinity
[64] and shares biological activities common to SP [65].
However unlike SP, it is primarily expressed in non-
neuronal tissues [65, 66]. The biological relevance of
HK-1 is still unclear, but some of the physiological activ-
ity previously assigned to SP might in fact be that of
HK-1, especially in the non-neuronal tissues [65, 67].
The cross-reactivity was reported in human samples, but
it is not known whether it applies to dogs. To date HK-1
and other novel SP-like peptides are described in man,
rat, and rabbit [66], but to the best of our knowledge,
not yet in dogs.
Conclusions
Contrary to the previous hypothesis, our results suggest
that the antinociceptive effect of IA BoNT A in the joint
might not be related to the inhibition of the release of
SP or to the release of PGE2. In addition, our findings
indicate that SF PGE2, but not serum PGE2, could be a
marker for chronic OA and pain in dogs. However,
neither SF nor serum SP seem to be good markers of
osteoarthritic pain in this species.
Endnotes
1Botox, Allergan, Inc., Irvine, CA
2SAS for Windows, versions 9.2 and 9.3, SAS Institute,
Inc., Cary, NC
3Substance P EIA Kit, Chayman Chemical Company,
Ann Arbor, MN
4PGE2 ELISA Kit, Enzo Life Sciences, Inc., Farmingdale,
NY
Table 2 Spearman’s rank correlation coefficients between synovial fluid and serum pain mediators and clinical variables of
osteoarthritic pain
Variable SF PGE2 Serum PGE2 SF SP Serum SP PVF VI HCPI Pain on palpation
SF PGE2 1.00 0.23 0.10 −0.05 −0.62* −0.61* 0.05 0.45*
Serum PGE2 0.23 1.00 −0.11 −0.48* 0.03 0.04 −0.08 −0.14
SF SP 0.10 −0.11 1.00 0.09 −0.02 0.02 0.02 −0.09
Serum SP −0.05 −0.48* 0.09 1.00 0.12 0.10 −0.03 −0.04
SF synovial fluid, PGE2 prostaglandin E2, SP substance P, PVF peak vertical force, VI vertical impulse, HCPI Helsinki Chronic Pain Index, Pain on palpation = subjective
evaluation of pain on palpation of the joint. *P < 0.05
Heikkilä et al. BMC Veterinary Research  (2017) 13:74 Page 9 of 11
5Quantikine ELISA, Canine TNF-α, R&D Systems,
Inc., Minneapolis, MN
6Kistler force plate, type 9286, Kistler Instrumente AG,
Amherst, NY
7Acquire 7.3, Sharon Software Inc., Dewitt, MI
Abbreviations
BoNT A: Botulinum neurotoxin A; CGRP: calcitonin gene-related peptide;
COX: Cyclooxygenase; HCPI: Helsinki Chronic Pain Index; HK-1: Hemokinin-1;
IA: Intra-articular; IQR: Interquartile range; OA: Osteoarthritis;
PGE2: Prostaglandin E2; PVF: Peak vertical force; SD: standard deviation;
SF: Synovial fluid; SP: Substance P; TNF-α: Tumor necrosis factor alpha;
VI: Vertical impulse
Acknowledgements
We thank Professor Satu Sankari for her help in the pain mediator analyses
and Jouni Junnila, M.Sc., for designing the statistical solutions.
Funding
This study was supported in part by the Finnish Veterinary Association, the
Finnish Veterinary Research Foundation, the Finnish Kennel Club, and the
ANIWEL Graduate School in Animal Welfare.
Availability of data and materials
The datasets generated and analysed during the current study are not
publicly available, because they are part of a PhD project that is still under
way. However, the datasets are available from the corresponding author on
reasonable request.
Authors’ contributions
HMH carried out the study and the laboratory analyses, analyzed the data,
and drafted the manuscript. AKHB assisted with designing the study,
analyzing the data, and finalizing the manuscript. JFI was responsible for the
laboratory analyses and assisted with designing the study and finalizing the
manuscript. OMLV assisted with designing the study and finalizing the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval
The study was approved by the Animal Experiment Board (ESAVI-2010-04178/Ym-23)
and the Finnish Medicines Agency. The owners of the dogs signed an
informed consent form having received information on the study.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Equine and Small Animal Medicine, Faculty of Veterinary
Medicine, University of Helsinki, P.O. Box 57, Helsinki 00014, Finland.
2Department of Musculoskeletal Biology, Institute of Aging and Chronic
Disease and School of Veterinary Science, University of Liverpool, Chester
High Road, Neston CH64 7TE, UK. 3Present address: ChesterGates Referral
Hospital, CVS Vets Ltd., Units E and F Telford Court, Chestergates Road,
Chester CH1 6LT, UK.
Received: 9 June 2015 Accepted: 8 March 2017
References
1. Johnston SA. Osteoarthritis: joint anatomy, physiology, and pathobiology.
Vet Clin N Am-Small. 1997;27:699–723.
2. Schaible HG, Ebersberger A, Banchet GS. Mechanisms of pain in arthritis.
Ann N Y Acad Sci. 2002;966:343–54.
3. Lee AS, Ellman MB, Yan D, et al. A current review of molecular mechanisms
regarding osteoarthritis and pain. Gene. 2013;527:440–7.
4. Garrett NE, Mapp PI, Cruwys SC, et al. Role of substance P in inflammatory
arthritis. Ann Rheum Dis. 1992;51:1014–8.
5. Keeble JE, Brain SD. A role for substance P in arthritis? Neurosci Lett. 2004;
361:176–9.
6. Kirker-Head CA, Chandna V, Agarwal R, et al. Concentrations of substance P
and prostaglandin E2 in synovial fluid of normal and abnormal joints of
horses. Am J Vet Res. 2000;61:714–8.
7. de Grauw JC, van de Lest CH, van Weeren R, et al. Arthrogenic lameness of
the fetlock: synovial fluid markers of inflammation and cartilage turnover in
relation to clinical joint pain. Equine Vet J. 2006;38:305–11.
8. Saxler G, Löer F, Skumavc M, et al. Localization of SP-and CGRP-
immunopositive nerve fibers in the hip joint of patients with painful
osteoarthritis and of patients with painless failed total hip arthroplasties. Eur
J Pain. 2007;11:67–74.
9. Nakayama K, Masuko S, Tsuruta T, et al. Vascularization and innervation of the
canine wrist joint synovial membrane. Tohoku J Exp Med. 1995;175:195–209.
10. Tamura R, Hanesch U, Schmidt RF, et al. Examination of colocalization of
calcitonin gene-related peptide- and substance P-like immunoreactivity in
the knee joint of the dog. Neurosci Lett. 1998;254:53–6.
11. Karahan S, Kincaid SA, Baird AN, et al. Distribution of beta-endorphin and
substance P in the shoulder joint of the dog before and after a low impact
exercise programme. Anat Histol Embryol. 2002;31:72–7.
12. Rialland P, Otis C, Moreau M, et al. Association between sensitization and
pain-related behaviours in an experimental canine model of osteoarthritis.
Pain. 2014;155:2071–9.
13. Natura G, Bar KJ, Eitner A, et al. Neuronal prostaglandin E2 receptor subtype
EP3 mediates antinociception during inflammation. Proc Natl Acad Sci USA.
2013;110:13648–53.
14. Trumble TN, Billinghurst RC, McIlwraith CW. Correlation of prostaglandin E2
concentrations in synovial fluid with ground reaction forces and clinical
variables for pain or inflammation in dogs with osteoarthritis induced by
transection of the cranial cruciate ligament. Am J Vet Res. 2004;65:1269–75.
15. Van Loon J, De Grauw J, Van Dierendonck M, et al. Intra‐articular opioid
analgesia is effective in reducing pain and inflammation in an equine LPS
induced synovitis model. Equine Vet J. 2010;42:412–9.
16. Brenner SS, Klotz U, Alscher DM, et al. Osteoarthritis of the knee–clinical
assessments and inflammatory markers. Osteoarthr Cartil. 2004;12:469–75.
17. Hogberg E, Stalman A, Wredmark T, et al. Opioid requirement after
arthroscopy is associated with decreasing glucose levels and increasing
PGE2 levels in the synovial membrane. Acta Orthop. 2006;77:657–61.
18. Halliday DA, McNeil JD, Betts WH, et al. The substance P fragment SP-(7–11)
increases prostaglandin E2, intracellular Ca2+ and collagenase production in
bovine articular chondrocytes. Biochem J. 1993;292:57–62.
19. Schaible H, Richter F, Ebersberger A, et al. Joint pain. Exp Brain Res. 2009;
196:153–62.
20. Kapoor M, Martel-Pelletier J, Lajeunesse D, et al. Role of proinflammatory
cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol.
2011;7:33–42.
21. Venn G, Nietfeld JJ, Duits AJ, et al. Elevated synovial fluid levels of
interleukin-6 and tumor necrosis factor associated with early experimental
canine osteoarthritis. Arthritis Rheum. 1993;36:819–26.
22. Kamm JL, Nixon AJ, Witte TH. Cytokine and catabolic enzyme expression in
synovium, synovial fluid and articular cartilage of naturally osteoarthritic
equine carpi. Equine Vet J. 2010;42:693–9.
23. Orita S, Koshi T, Mitsuka T, et al. Associations between proinflammatory
cytokines in the synovial fluid and radiographic grading and pain-related
scores in 47 consecutive patients with osteoarthritis of the knee. BMC
Musculoskelet Disord. 2011;12:144.
24. Wheeler A, Smith HS. Botulinum toxins: mechanisms of action,
antinociception and clinical applications. Toxicology. 2013;306:124–46.
25. Borodic GE, Acquadro M, Johnson EA. Botulinum toxin therapy for pain and
inflammatory disorders: mechanisms and therapeutic effects. Expert Opin
Investig Drugs. 2001;10:1531–44.
26. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root
ganglia neurons to Clostridium botulinum neurotoxins. Toxicon.
2000;38:245–58.
27. Ishikawa H, Mitsui Y, Yoshitomi T, et al. Presynaptic effects of botulinum
toxin type A on the neuronally evoked response of albino and pigmented
rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol. 2000;44:106–9.
Heikkilä et al. BMC Veterinary Research  (2017) 13:74 Page 10 of 11
28. Chuang YC, Yoshimura N, Huang CC, et al. Intraprostatic botulinum toxin A
injection inhibits cyclooxygenase-2 expression and suppresses prostatic pain
on capsaicin induced prostatitis model in rat. J Urol. 2008;180:742–8.
29. Chuang YC, Yoshimura N, Huang CC, et al. Intravesical botulinum toxin A
administration inhibits COX-2 and EP4 expression and suppresses bladder
hyperactivity in cyclophosphamide-induced cystitis in rats. Eur Urol.
2009;56:159–66.
30. Heikkilä HM, Hielm-Björkman AK, Morelius M, et al. Intra-articular botulinum
toxin A for the treatment of osteoarthritic joint pain in dogs: a randomized,
double-blinded, placebo-controlled clinical trial. Vet J. 2014;200:162–9.
31. Mahowald ML, Krug HE, Singh JA, et al. Intra-articular Botulinum Toxin Type
A: A new approach to treat arthritis joint pain. Toxicon. 2009;54:658–67.
32. Singh JA, Mahowald ML, Noorbaloochi S. Intra-articular botulinum toxin A
for refractory shoulder pain: a randomized, double-blinded, placebo-
controlled trial. Transl Res. 2009;153:205–16.
33. Boon AJ, Smith J, Dahm DL, et al. Efficacy of Intra-Articular Botulinum Toxin
Type A in Painful Knee Osteoarthritis: A Pilot Study. PM&R. 2010;2:268–76.
34. Lee JH, Lee SH, Song SH. Clinical effectiveness of botulinum toxin A
compared to a mixture of steroid and local anesthetics as a treatment for
sacroiliac joint pain. Pain Med. 2010;11:692–700.
35. DePuy T, Howard R, Keegan K, et al. Effects of Intra-articular Botulinum
Toxin Type A in an Equine Model of Acute Synovitis: A Pilot Study. Am J
Phys Med Rehab. 2007;86:777–83.
36. Cook J, Kuroki K, Visco D, et al. The OARSI histopathology initiative–
recommendations for histological assessments of osteoarthritis in the dog.
Osteoarthr Cartil. 2010;18:66–79.
37. Innes JF. Arthritis. In: Tobias KM, Johnston SA, editors. Veterinary Surgery:
Small Animal. St. Louis: Elsevier; 2012. p. 1078–112.
38. Corbally N, Powell D, Tipton KF. The binding of endogenous and exogenous
substance-P in human plasma. Biochem Pharmacol. 1990;39:1161–6.
39. Campbell DE, Raftery N, Tustin III R, et al. Measurement of plasma-derived
substance P: biological, methodological, and statistical considerations. Clin
Vaccine Immunol. 2006;13:1197–203.
40. Hielm-Björkman AK, Rita H, Tulamo RM. Psychometric testing of the Helsinki
chronic pain index by completion of a questionnaire in Finnish by owners
of dogs with chronic signs of pain caused by osteoarthritis. Am J Vet Res.
2009;70:727–34.
41. Singh JA. Botulinum toxin therapy for osteoarticular pain: an evidence-
based review. Ther Adv Musculoskel Dis. 2010;2:105–18.
42. Durham PL, Cady R, Cady R. Regulation of Calcitonin Gene‐Related Peptide
Secretion From Trigeminal Nerve Cells by Botulinum Toxin Type A:
Implications for Migraine Therapy. Headache. 2004;44:35–43.
43. Purkiss J, Welch M, Doward S, et al. Capsaicin-stimulated release of
substance P from cultured dorsal root ganglion neurons: involvement of
two distinct mechanisms. Biochem Pharmacol. 2000;59:1403–6.
44. McMahon H, Foran P, Dolly J, et al. Tetanus toxin and botulinum toxins type
A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-
enkephalin release from synaptosomes. Clues to the locus of action. J Biol
Chem. 1992;267:21338–43.
45. Rapp DE, Turk KW, Bales GT, et al. Botulinum toxin type A inhibits
calcitonin gene-related peptide release from isolated rat bladder. J Urol.
2006;175:1138–42.
46. Lucioni A, Bales GT, Lotan TL, et al. Botulinum toxin type A inhibits sensory
neuropeptide release in rat bladder models of acute injury and chronic
inflammation. BJU Int. 2008;101:366–70.
47. Chuang Y, Yoshimura N, Huang CC, et al. Intravesical botulinum toxin A
administration produces analgesia against acetic acid induced bladder pain
responses in rats. J Urol. 2004;172:1529–32.
48. Cui M, Khanijou S, Rubino J, et al. Subcutaneous administration of
botulinum toxin A reduces formalin-induced pain. Pain. 2004;107:125–33.
49. Lands WE. The biosynthesis and metabolism of prostaglandins. Annu Rev
Physiol. 1979;41:633–52.
50. Benschop RJ, Collins EC, Darling RJ, et al. Development of a novel antibody
to Calcitonin Gene-Related Peptide for the treatment of osteoarthritis-
related pain. Osteoarthr Cartil. 2014;22:578–85.
51. Caron JP, Bowker RM, Abhold RH, et al. Substance P in the synovial
membrane and fluid of the equine middle carpal joint. Equine Vet J.
1992;24:364–6.
52. Gotoh M, Hamada K, Yamakawa H, et al. Increased substance P in
subacromial bursa and shoulder pain in rotator cuff diseases. J Orthop Res.
1998;16:618–21.
53. Holmlund A, Ekblom A, Hansson P, et al. Concentrations of neuropeptides
substance P, neurokinin A, calcitonin gene-related peptide, neuropeptide Y
and vasoactive intestinal polypeptide in synovial fluid of the human
temporomandibular joint. A correlation with symptoms, signs and
arthroscopic findings. Int J Oral Maxillofac Surg. 1991;20:228–31.
54. Sato J, Segami N, Yoshitake Y, et al. Specific expression of substance P in
synovial tissues of patients with symptomatic, non-reducing internal
derangement of the temporomandibular joint: comparison with clinical
findings. Br J Oral Maxillofac Surg. 2007;45:372–7.
55. Appelgren A, Appelgren B, Kopp S, et al. Substance P-associated increase of
intra-articular temperature and pain threshold in the arthritic TMJ. J Orofac
Pain. 1998;12:101–7.
56. Schmidt MJ, Roth J, Ondreka N, et al. A potential role for substance P and
interleukin-6 in the cerebrospinal fluid of Cavalier King Charles Spaniels with
neuropathic pain. J Vet Intern Med. 2013;27:530–5.
57. Carter SD, Barnes A, Gilmore WH. Canine rheumatoid arthritis and
inflammatory cytokines. Vet Immunol Immunopathol. 1999;69:201–14.
58. Hay CW, Chu Q, Budsberg SC, et al. Synovial fluid interleukin 6, tumor
necrosis factor, and nitric oxide values in dogs with osteoarthritis secondary
to cranial cruciate ligament rupture. Am J Vet Res. 1997;58:1027–32.
59. Bertone AL, Palmer JL, Jones J. Synovial fluid cytokines and eicosanoids as
markers of joint disease in horses. Vet Surg. 2001;30:528–38.
60. Abe H, Sakai T, Ando W, et al. Synovial joint fluid cytokine levels in hip
disease. Rheumatology. 2014;53:165–72.
61. Kraus VB, Huebner JL, Fink C, et al. Urea as a passive transport marker for
arthritis biomarker studies. Arthritis Rheum. 2002;46:420–7.
62. Bileviciute I, Lundeberg T, Ekblom A, et al. Bilateral changes of substance P-,
neurokinin A-, calcitonin gene-related peptide- and neuropeptide Y-like
immunoreactivity in rat knee joint synovial fluid during acute monoarthritis.
Neurosci Lett. 1993;153:37–40.
63. Kidd BL, Cruwys SC, Garrett NE, et al. Neurogenic influences on contralateral
responses during experimental rat monoarthritis. Brain Res. 1995;688:72–6.
64. Bellucci F, Carini F, Catalani C, et al. Pharmacological profile of the novel
mammalian tachykinin, hemokinin 1. Br J Pharmacol. 2002;135:266–74.
65. Zhang Y, Lu L, Furlonger C, et al. Hemokinin is a hematopoietic-specific
tachykinin that regulates B lymphopoiesis. Nat Immunol. 2000;1:392–7.
66. Page NM. Hemokinins and endokinins. Cell Mol Life Sci. 2004;61:1652–63.
67. Kurtz MM, Wang R, Clements MK, et al. Identification, localization and
receptor characterization of novel mammalian substance P-like peptides.
Gene. 2002;296:205–12.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Heikkilä et al. BMC Veterinary Research  (2017) 13:74 Page 11 of 11
